ApicHope Pharmaceutical Group Co., Ltd. CLass A

ApicHope Pharmaceutical Group Co., Ltd. CLass A

SSZSE:300723
26.16
CNY
-0.49
(-1.84%)
0.39EPS
82.52P/E
15.08BMarket Cap
Apr 23Next Earn
ApicHope Pharmaceutical Group Co., Ltd. CLass A
SZSE:300723
(Shenzhen Stock Exchange)

Recent

price

26.16

P/E

ratio

82.52

div

yld

0.40%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.57
1.83
3.15
3.85
4.14
3.28
3.8
3.86
5.21
5.31
5.54
3.21
2.06
1.64
Revenue per Share
0.1
0.09
0.19
0.42
0.47
0.48
0.33
0.52
0.73
0.68
0.41
-1.2
-0.75
0.4
Basic EPS, GAAP
0.15
-0.24
-0.02
0.36
0.39
-0.04
0.41
-0.09
-0.29
-0.3
0.27
-1.93
-0.18
- -
Free Cash Flow per Basic Share
0.02
0.05
0.45
0.06
0.05
0.09
0.08
0.08
0.09
0.15
0.15
0.24
0.13
0.11
Dividend per Share
0.55
0.39
0.6
1.03
2.56
2.98
3.05
3.42
4.34
4.75
5.55
4.16
3.03
3.9
Book Value per Share
0.27
-0.08
0.09
0.5
2.19
2.18
2.33
2.73
3.25
3.65
4.54
3.18
2.04
2.97
Tangible Book Value per Share
324
432
326
325
333
436
431
434
422
429
452
452
452
449
Basic Weighted Avg Shares
508
793
1,028
1,251
1,380
1,430
1,637
1,675
2,199
2,280
2,503
1,450
932
735
Sales/Revenue/Turnover
10
9.47
10.21
13
14.43
16.75
13.82
11.84
12.68
14.65
10.97
-17.73
-26.83
-35.8
Operating Margin (%)
13
18
28
31
34
36
38
41
73
97
182
204
215
- -
Depreciation Expense
33
40
60
137
157
208
144
226
307
291
185
-540
-338
181
Net Income, GAAP
25.37
28.78
26.59
17.26
16.33
14.78
24.61
18.17
19.12
19.7
37.84
- -
- -
- -
Effective Tax Rate (%)
6.5
5.09
5.88
10.98
11.35
14.57
8.78
13.47
13.96
12.75
7.37
-37.24
-36.23
24.62
Profit Margin (%)
-71
81
148
283
1,036
795
794
634
358
202
-129
-474
-35
531
Working Capital
- -
300
296
291
251
- -
- -
95
353
590
186
613
1,370
1,192
LT Debt
186
128
201
336
1,108
1,299
1,341
1,495
2,018
2,166
2,598
1,936
1,407
1,802
Total Equity
- -
9.31
10.68
18.83
14.88
13.45
8.83
9.65
8.98
6.79
3.86
- -
- -
- -
Return on Invested Capital (%)
- -
14.16
15.61
25.41
17.03
15.22
9.55
13.8
13.66
10.3
7.15
- -
- -
- -
Return on Capital (%)
- -
26.46
37.37
51.92
21.76
17.31
10.94
16.04
18.27
14.81
8.07
-24.54
-20.8
10.1
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
916
827
826
LT Borrowings
1,167
1,225
1,190
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
452
452
453
Market Capitalization
14,648
16,839
15,077

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,076
1,857
1,725
Cash, Cash Equivalents & STI
1,401
1,246
1,153
Accounts Receivable, Net
287
178
156
Inventories
221
207
192
Total Current Liabilities
1,432
1,250
1,194
Payables & Accruals
- -
- -
- -
ST Debt
916
827
826
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
33.85%
1.89%
-27.34%
Free Cash Flow
-376.9%
-173.51%
-90.67%
Net Income, GAAP
-23.54%
-87.14%
-37.45%
Sales/Revenue/Turnover
1.94%
-6.61%
-35.72%
Total Cash Common Dividend
14.03%
17.67%
-47.47%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
623
290
327
210
1,450
2025
377
207
- -
118
932
2026
385
106
125
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
-0.12
-0.65
-0.66
-1.2
2025
0.13
-0.29
- -
-0.45
-0.75
2026
1.32
-0.24
-0.23
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.25
0.01
-0.03
0.24
2025
0.02
0.04
- -
0.03
0.13
2026
0.04
0.02
0.02
- -
- -
Business
ApicHope Pharmaceutical Group Co., Ltd. (300723.SZ) engages in the research, development, production and sale of pharmaceutical drugs primarily in China, with a focus on pediatrics and chronic disease medications; its core products include pediatric medicines such as Fuganlin oral liquid, Yiqi Jianpi oral liquid, Carboxymestrine oral solution, Xiao'er Kechuanling oral liquid, Clindamycin Palmitate Hydrochloride dispersible tablets, Acetylkitasamycin for suspension and Qinxiangqingjie oral liquid; chronic disease drugs comprise hepatocyte growth stimulating hormone and pentoxifylline for injections, Kangshen granules, Uqingshu granules, Shenbai lotion, compound monoammonium glycyrrhizinate S and lansoprazole for injections, and Houttuynia sodium; additional offerings cover anti-infection, cardiovascular, genitourinary, respiratory, liver and digestion, dermatological, anti-inflammatory and analgesic products, alongside innovative pharmaceuticals and vaccines. Founded in 2002 and headquartered in Guangzhou, China, the company operates through the full pharmaceutical industry chain, including subsidiaries like Guangzhou Redbud Pharmaceutical Co., Ltd., and maintains production facilities recognized as a National Green Factory and 2024 Guangdong Provincial Manufacturing Single Champion Enterprise. In December 2024, it changed its name from ApicHope Pharmaceutical Co., Ltd. to ApicHope Pharmaceutical Group Co., Ltd.; recent developments include its wholly-owned subsidiary obtaining clinical trial approval for Fuganlin Granules, approval for compound polyethylene glycol (3350) electrolyte dispersion registration certificate, and a new drug clinical trial nod for an endometriosis treatment, alongside ongoing partnerships such as the joint venture with Arthrosi Therapeutics via Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. to advance AR882 for gout and AR035 for oncology in Greater China.